Publications by authors named "Cory Mavis"

Claim this Profile
T
Targeted BET inhibition with OPN-51107 synergizes with venetoclax in chronic lymphocytic leukemia.
Kevin G Zablonski, Sydney A Skupa, Alexandria P Eiken, Suchitra Sundaram, Cory Mavis

Leuk Lymphoma· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small-molecule MMRi36 induces apoptosis in p53-mutant lymphomas by targeting MDM2/MDM4/XIAP for degradation.
Rati Lama, Wenjie Wu, Cory K Mavis, Federico M Ruiz, Javier Querol-García

Front Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Lan-Hsi Lin, Mohammad Ghasemi, Sarah M Burke, Cory K Mavis, Jenna R Nichols

Target Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early changes in soluble intracellular adhesion molecule-1 as prognostic biomarkers to immune checkpoint inhibitor.
Dongmei Ji, Shiyu Jiang, Qunling Zhang, Y Ken Wang, Jian Zhang, Cory Mavis

Clin Transl Sci· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AMG176, an MCL-1 inhibitor, is active in pre-clinical models of aggressive B-cell lymphomas.
Pallawi Torka, Tara Russell, Cory Mavis, Juan Gu, Paola Ghione

Leuk Lymphoma· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL.
Pallawi Torka, Adrienne Groman, Jerry Wong, Jenna Nichols, Angela Kader, Cory Mavis

Blood Adv· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small molecule MMRi62 targets MDM4 for degradation and induces leukemic cell apoptosis regardless of p53 status.
Rati Lama, Chao Xu, Samuel L Galster, Javier Querol-García, Scott Portwood, Cory K Mavis

Front Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study.
Pallawi Torka, Othman S Akhtar, Nishitha M Reddy, Bora E Baysal, Angela Kader, Cory Mavis

Cancer· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies.
Paola Ghione, Juan J Gu, Kristopher Attwood, Pallawi Torka, Shipra Goel, Cory Mavis

Blood· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overcoming resistance to rituximab in relapsed non-Hodgkin lymphomas by antibody-polymer drug conjugates actively targeted by anti-CD38 daratumumab.
Ondřej Lidický, Pavel Klener, Daniela Machová, Petra Vočková, Eva Pokorná, Cory Mavis

J Control Release· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The adhesion molecule ICAM-1 in diffuse large B-cell lymphoma post-rituximab era: relationship with prognostic importance and rituximab resistance.
Yizhen Liu, Juan J Gu, Ling Yang, Ping-Chiao Tsai, Ye Guo, Cory Mavis

Aging (Albany NY)· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metformin sensitizes therapeutic agents and improves outcome in pre-clinical and clinical diffuse large B-cell lymphoma.
Anil R Singh, Juan J Gu, Qunling Zhang, Pallawi Torka, Suchitra Sundaram, Cory Mavis

Cancer Metab· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pevonedistat, a NEDD8-Activating Enzyme Inhibitor, Induces Apoptosis and Augments Efficacy of Chemotherapy and Small Molecule Inhibitors in Pre-clinical Models of Diffuse Large B-cell Lymphoma.
Pallawi Torka, Cory Mavis, Shalin Kothari, Sarah Belliotti, Juan Gu

EJHaem· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The SMAC mimetic LCL-161 displays antitumor activity in preclinical models of rituximab-resistant B-cell lymphoma.
Kyle Runckel, Matthew J Barth, Cory Mavis, Juan J Gu, Francisco J Hernandez-Ilizaliturri

Blood Adv· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma.
Maria Bhatti, Thomas Ippolito, Cory Mavis, Juan Gu, Mitchell S Cairo

Oncotarget· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B-cell Non-Hodgkin Lymphoma.
Pallawi Torka, Priyank Patel, Wei Tan, Gregory Wilding, Seema A Bhat, Cory Mavis

Clin Lymphoma Myeloma Leuk· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development.
Juan J Gu, Anil Singh, Kai Xue, Cory Mavis, Matthew Barth

Oncotarget· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mitotic catastrophe and cell cycle arrest are alternative cell death pathways executed by bortezomib in rituximab resistant B-cell lymphoma cells.
Juan J Gu, Gregory P Kaufman, Cory Mavis, Myron S Czuczman, Francisco J Hernandez-Ilizaliturri

Oncotarget· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo.
Natalie M Czuczman, Matthew J Barth, Juan Gu, Vishala Neppalli, Cory Mavis

Blood· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Kai Xue, Juan J Gu, Qunling Zhang, Cory Mavis, Francisco J Hernandez-Ilizaliturri

J Cancer Res Clin Oncol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma.
Matthew J Barth, Cory Mavis, Myron S Czuczman, Francisco J Hernandez-Ilizaliturri

Clin Cancer Res· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
Sarah Frys, Zachary Simons, Qiang Hu, Matthew J Barth, Juan J Gu, Cory Mavis

Br J Haematol· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.
Magdalena Klanova, Lucie Lorkova, Ondrej Vit, Bokang Maswabi, Jan Molinsky, Cory Mavis

Mol Cancer· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical models.
Juan J Gu, Francisco J Hernandez-Ilizaliturri, Cory Mavis, Natalie M Czuczman, George Deeb

Anticancer Drugs· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.
Juan J Gu, Francisco J Hernandez-Ilizaliturri, Gregory P Kaufman, Natalie M Czuczman, Cory Mavis

Br J Haematol· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis